Drugs in Dev. Nephrology
Phase IV
Germany 
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kerendia (Finerenone) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Kerendia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the exploratory post hoc analysis of FIDELITY also highlight the potential of Kerendia™ (finerenone) to reduce the incidence of hospitalization for heart failure (HHF), with a more pronounced effect in patients with left ventricular hypertrop...
Product Name : Kerendia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
